Takeda begins patient enrolment in Phase III trial of myeloma drug ixazomib
The Phase III trial is designed to show whether sustained proteasome inhibition, delivered orally, improves the long term clinical outcomes of people living with MM. In the trial,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.